Recombinant human erythropoietin in the prevention of chemotherapy- induced anaemia in children with malignant solid tumours

C. Csáki, T. Ferencz, D. Schuler, J. D. Borsi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

This prospective, randomised pilot study was designed to evaluate safety, feasibility and efficacy of recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia in children with solid tumours. 20 children (age 4-18 years) undergoing cyclic combination chemotherapy were randomised either to a control group or to receive rhEPO at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks or three chemotherapy cycles. Of 15 evaluable patients, 8 were randomised to the rhEPO group and 7 to the control group. RhEPO- treated patients showed an increase in the haematocrit over the first 8 weeks of therapy, with a significantly higher mean haematocrit at week 8 (33.2 ± 2.1% versus 39.3 ± 4.2% in the control and rhEPO groups, respectively, P

Original languageEnglish
Pages (from-to)364-367
Number of pages4
JournalEuropean Journal of Cancer
Volume34
Issue number3
DOIs
Publication statusPublished - Feb 1998

Fingerprint

Erythropoietin
Anemia
Drug Therapy
Hematocrit
Neoplasms
Control Groups
Combination Drug Therapy
Safety
Therapeutics

Keywords

  • Chemotherapy-induced anaemia
  • Children
  • Malignant solid tumour
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Recombinant human erythropoietin in the prevention of chemotherapy- induced anaemia in children with malignant solid tumours. / Csáki, C.; Ferencz, T.; Schuler, D.; Borsi, J. D.

In: European Journal of Cancer, Vol. 34, No. 3, 02.1998, p. 364-367.

Research output: Contribution to journalArticle

@article{8336f2ce052e4b229f625145b9d900b7,
title = "Recombinant human erythropoietin in the prevention of chemotherapy- induced anaemia in children with malignant solid tumours",
abstract = "This prospective, randomised pilot study was designed to evaluate safety, feasibility and efficacy of recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia in children with solid tumours. 20 children (age 4-18 years) undergoing cyclic combination chemotherapy were randomised either to a control group or to receive rhEPO at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks or three chemotherapy cycles. Of 15 evaluable patients, 8 were randomised to the rhEPO group and 7 to the control group. RhEPO- treated patients showed an increase in the haematocrit over the first 8 weeks of therapy, with a significantly higher mean haematocrit at week 8 (33.2 ± 2.1{\%} versus 39.3 ± 4.2{\%} in the control and rhEPO groups, respectively, P",
keywords = "Chemotherapy-induced anaemia, Children, Malignant solid tumour, Recombinant human erythropoietin",
author = "C. Cs{\'a}ki and T. Ferencz and D. Schuler and Borsi, {J. D.}",
year = "1998",
month = "2",
doi = "10.1016/S0959-8049(97)10065-X",
language = "English",
volume = "34",
pages = "364--367",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Recombinant human erythropoietin in the prevention of chemotherapy- induced anaemia in children with malignant solid tumours

AU - Csáki, C.

AU - Ferencz, T.

AU - Schuler, D.

AU - Borsi, J. D.

PY - 1998/2

Y1 - 1998/2

N2 - This prospective, randomised pilot study was designed to evaluate safety, feasibility and efficacy of recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia in children with solid tumours. 20 children (age 4-18 years) undergoing cyclic combination chemotherapy were randomised either to a control group or to receive rhEPO at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks or three chemotherapy cycles. Of 15 evaluable patients, 8 were randomised to the rhEPO group and 7 to the control group. RhEPO- treated patients showed an increase in the haematocrit over the first 8 weeks of therapy, with a significantly higher mean haematocrit at week 8 (33.2 ± 2.1% versus 39.3 ± 4.2% in the control and rhEPO groups, respectively, P

AB - This prospective, randomised pilot study was designed to evaluate safety, feasibility and efficacy of recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia in children with solid tumours. 20 children (age 4-18 years) undergoing cyclic combination chemotherapy were randomised either to a control group or to receive rhEPO at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks or three chemotherapy cycles. Of 15 evaluable patients, 8 were randomised to the rhEPO group and 7 to the control group. RhEPO- treated patients showed an increase in the haematocrit over the first 8 weeks of therapy, with a significantly higher mean haematocrit at week 8 (33.2 ± 2.1% versus 39.3 ± 4.2% in the control and rhEPO groups, respectively, P

KW - Chemotherapy-induced anaemia

KW - Children

KW - Malignant solid tumour

KW - Recombinant human erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=0032005594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032005594&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(97)10065-X

DO - 10.1016/S0959-8049(97)10065-X

M3 - Article

C2 - 9640223

AN - SCOPUS:0032005594

VL - 34

SP - 364

EP - 367

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -